TP53 and neoplasm: As expected, based on the mechanism of activity of MDM2 inhibitors, evidence from the aforementioned clinical studies suggests that the expression levels of MDM2 in tumor cells could serve as predictive and early response biomarker for the treatment of patients with MDM2-p53 targeted therapies [16].